Meloxicam and Beta haemolytic streptococcal infection - a phase IV clinical study of FDA data

Summary:

Beta haemolytic streptococcal infection is reported as a side effect among people who take Meloxicam (meloxicam), especially for people who are female, 60+ old, also take Methotrexate,.

The phase IV clinical study analyzes which people have Beta haemolytic streptococcal infection when taking Meloxicam. It is created by eHealthMe based on reports of 64,757 people who have side effects when taking Meloxicam from the FDA, and is updated regularly.

What is Meloxicam?

Meloxicam has active ingredients of meloxicam. It is often used in arthritis. eHealthMe is studying from 68,016 Meloxicam users. Check the latest studies of Meloxicam.

What is Beta haemolytic streptococcal infection?

Beta haemolytic streptococcal infection (infection with streptococcus pyogenes, a beta-haemolytic bacterium cause mild to moderately severe respiratory tract, skin, and soft tissue) is found to be associated with 248 drugs and 405 conditions by eHealthMe. Check the latest studies of Beta haemolytic streptococcal infection.

On Jul, 15, 2026

64,757 people reported to have side effects when taking Meloxicam.
Among them, 14 people (0.02%) have Beta haemolytic streptococcal infection.

Could Meloxicam cause Beta haemolytic streptococcal infection?

Among these 14 people:

What is the gender of people who have Beta haemolytic streptococcal infection when taking Meloxicam? *

female: 100 %
male: 0.0 %

What is the age of people who have Beta haemolytic streptococcal infection when taking Meloxicam? *

What are other drugs people take besides Meloxicam? *

What are other side effects people have besides Beta haemolytic streptococcal infection? *

Multi-Organ Failure (multisystem organ failure): 14 people, 100.00%
Sepsis (a severe blood infection that can lead to organ failure and death): 13 people, 92.86%
Streptococcal Sepsis (whole body inflammation by streptococcal): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Meloxicam and have Beta haemolytic streptococcal infection?

- Check whether Beta haemolytic streptococcal infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Meloxicam:

Meloxicam (68,016 reports)

Beta haemolytic streptococcal infection treatments and more:

Beta haemolytic streptococcal infection (1,868 reports)

How severe was Beta haemolytic streptococcal infection and when was it recovered:

Beta haemolytic streptococcal infection in Meloxicam

Expand to all the drugs that have ingredients of meloxicam:

Beta haemolytic streptococcal infection and drugs with ingredients of meloxicam

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Meloxicam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Beta haemolytic streptococcal infection:

Beta haemolytic streptococcal infection (248 drugs)

Browse all the conditions that are associated with Beta haemolytic streptococcal infection:

Beta haemolytic streptococcal infection (405 conditions)

Related publications that referenced our studies

Lai SW, Lin CL, Liao KF, "Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case–Control Study", Clinical drug investigation, 2015 Oct .
Lai SW, Lin CL, Liao KF, "Association of Meloxicam Use with the Risk of Acute Pancreatitis: A Case–Control Study", Clinical drug investigation, 2015 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on meloxicam (the active ingredients of Meloxicam) and Meloxicam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.